Epoprostenol in primary pulmonary hypertension

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Primary pulmonary hypertension (PPH) is a rare condition causing heart failure symptoms with a low 5-year survival rate.
• Current PPH therapies include vasodilators, anticoagulation, oxygen, and lung transplantation.

Purpose of the Study:

• To review the epidemiology, pathophysiology, and treatment of PPH.
• To evaluate clinical data on epoprostenol for PPH treatment.

Main Methods:

• Conducted a MEDLINE search from 1966 to 1998 and reviewed bibliographic lists.
• Included English-language clinical studies of epoprostenol in PPH, excluding incomplete descriptions.
• Evaluated study design, population, methods, clinical outcomes, and adverse effects.

Main Results:

• Epoprostenol improved hemodynamic parameters (cardiac output, pulmonary artery pressure, pulmonary vascular resistance) in PPH patients.
• Epoprostenol demonstrated improvements in exercise capacity, New York Heart Association (NYHA) functional class, and survival rates.
• Indicated for severe PPH (NYHA class III-IV) unresponsive to vasodilators or calcium-channel blockers, requiring continuous infusion and specialized handling due to short stability and refrigeration needs.

Conclusions:

• Epoprostenol therapy offers significant improvements in hemodynamics and clinical outcomes for severe PPH.
• Requires intensive patient education and medical supervision, but enhances quality of life and potentially postpones lung transplantation.